The complex therapy of type 2 diabetes mellitus. II. Clinical significance, therapeutical tools and cost-effectiveness of the treatment of hypertension, dyslipidaemia and hypercoagulability associated with diabetes mellitus;A 2-es típusú diabetes mellitus komplex terápiája. II. A diabeteshez társult hypertonia, dyslipidaemia és thrombosis-hajlam kezelésének klinikai jelentösége, gyógyszeres lehetöségei és költség-hatékonysága

Orvoskepzes

Volumn 76, Issue 3, 2001, Pages 200-209

  Gero L ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ACIPIMOX; ALCOLEX; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBOHYDRATE; CHLORTALIDONE; CLOPIDOGREL; COLESTYRAMINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; FIBRINOGEN RECEPTOR ANTAGONIST; IMIDAZOLINE RECEPTOR; LIPID; METOPROLOL; MOXONIDINE; NIFEDIPINE; PROBUCOL; RILMENIDINE; STATINE DERIVATIVE; TICLOPIDINE;

CARBOHYDRATE METABOLISM; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DIABETES CONTROL; DIABETIC ANGIOPATHY; DYSLIPIDEMIA; HEALTH CARE COST; HUMAN; HYPERCOAGULABILITY; HYPERTENSION; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; RISK FACTOR; THROMBOCYTE AGGREGATION; TREATMENT OUTCOME;

EID: 0034778257     PISSN: 00306037     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Long-term weight loss and changes in blood pressure: Results of the Trials of Hypertension Prevention, Phase II
2. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38)
3. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomized trial
4. Effect of ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: Data from the GISSI-3 study
5. Uniformity of captopril benefit in the SAVE study: Subgroup analysis
6. Angiotensin-converting enzyme inhibition after myocardial infarction: The Trandolapril Cardiac Evaluation Study
7. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
8. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy
9. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin dependent diabetes mellitus
10. Effect of lisinopril on progression of retinopathy in normotensive people with type I diabetes
11. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: The Steno 2 randomised study
12. Angiotensin II potentiates vascular endothelial growth factor-induced angiogenic activity in retinal microcapillary endothelial cells
13. Angiotensin converting enzyme inhibition ameliorates retinal overexpression of vascular endothelial growth factor and retinal hyperpermeability
14. Angiotensin konvertáló enzimbénítók alkalmazása diabetes mellitusban
15. Angiotensin II receptor blockers - Equal or preferred substitutes for ACE inhibition?
16. ACE inhibition and ANG II receptor blockade improve glomerular size-selectivity in IgA nephropathy
17. Additive effects of losartan and cnalapril on blood pressure and plasma renin
18. Outcome results of the fosinopril versus amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM
19. Isradipine, raised glycosylated haemoglobin, and risk of cardiovascular events
20. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin dependent diabetes and hypertension
21. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomized trial
22. Effects of calcium-channel blockade in older subjects with diabetes and systolic hypertension
23. Morbidity and mortality in patients randomised to double-blind treatment with long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT)
24. Randomised trial of effects of calcium antagonsists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: The Nordic Diltiazem (NORDIL) study
25. Effects of a fixed dose combination of either amlodipine, benazapril, or their combination on glomerulosclerosis and proteinuria
26. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: A meta-analysis of randomized controlle trials
27. Effects of ACE inhibitors, calcium antagonists, and other bloodpressure-lowering drugs: Results of prospectively designed overviews of randomized trials
28. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 39)
29. Impact of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy
30. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension
31. Indapamide is as effective as captopril in the control of microalbuminuria in diabetes
32. "Tenaxum diabetesben" vizsgȧlȯcsoport. A rilmenidin (Tenaxum) hatékonysȧgának és biztonsȧgosságának vizsgálata enyhe és közȧpsu̇lyos hypertoniával szövödött, 2-es típusú diabetes mellitusban
33. A rilmenidin hatása a balkamra-hypertrophia̧ra enyhe-középsúlyos hypertoniában (A hazai multicentrikus echocardiographiás vizsgálat eredményei)
34. Major cardiovascular events in hypertensive patients randomized to doxazosine vs. chlorthalidone
35. Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: Relative conribution of small dense LDL to coronary heart disease risk
36. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandianavian Simvastatin Survival Study (4S)
37. Cholesterol lowering with simvastatin sinivastatin improves prognosis of diabetic patients with coronary heart disease
38. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
39. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
40. Reduced coronary events in simvastatintreated patients with coronary heart disease and diabetes or impaired fasting glucose levels
41. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the cholesterol and recurrent events trial
42. Serum cholesterol, blood pressure, and mortality: Implications from a cohort of 361 662 men
43. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: Implications for treatment
44. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients
45. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
46. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: The diabetes atherosclerosis intervention study, a randomized study
47. Acipimox hatása a diabetes mellitushoz társult hyperlipoproteinacmiákra
48. Long-term safety of statin-fibrate combination therapy in patients with coronary disease
49. Aspirin therapy in diabetes
50. Aspirin effects on morbidity and mortality in patients with diabetes mellitus: Early treatment diabetic retinopathy study report
51. Collaborative overview of randomized trials of antiplatelet therapyI : Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients
52. Effects of abeiximab, tielopidine and combined abciximab/ticlopidine therapy on platelet and leucocyte function in patients undergoing coronary angioplasty
53. Pronounced benefit of coronary stenting and adjunctive platelet glycoprotein IIb/IIIa inhibition in complex atherosclerotic lesions
54. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: Economic analysis alongside randomized controlled trial (UKPDS 41)
55. The cost-effectiveness of lipid lowering in patients with diabetes: Results from the 4S trial